278 citations
,
March 2013 in “Gut” In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
107 citations
,
December 2003 in “Dermatologic Therapy” This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.
71 citations
,
May 2024 in “New England Journal of Medicine” This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.
64 citations
,
January 2009 in “Canadian Journal of Gastroenterology” This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.